ENDARI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Endari, and what generic alternatives are available?
Endari is a drug marketed by Emmaus Medcl and is included in one NDA.
The generic ingredient in ENDARI is l-glutamine. There are forty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the l-glutamine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ENDARI?
- What are the global sales for ENDARI?
- What is Average Wholesale Price for ENDARI?
Summary for ENDARI
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 188 |
Clinical Trials: | 3 |
Patent Applications: | 2,739 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ENDARI |
What excipients (inactive ingredients) are in ENDARI? | ENDARI excipients list |
DailyMed Link: | ENDARI at DailyMed |
![ENDARI drug patent expirations Drug patent expirations by year for ENDARI](/p/graph/s/t/ENDARI-patent-expirations.png)
![Drug Prices for ENDARI](/p/graph/drug-price/ENDARI.png)
Recent Clinical Trials for ENDARI
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Jun Gong, MD | Phase 1 |
Emmaus Medical, Inc. | Phase 1 |
Emmaus Medical, Inc. | Phase 4 |
Pharmacology for ENDARI
Drug Class | Amino Acid |
US Patents and Regulatory Information for ENDARI
ENDARI is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting ENDARI
TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Emmaus Medcl | ENDARI | l-glutamine | FOR SOLUTION;ORAL | 208587-001 | Jul 7, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |